Stoke Therapeutics, Inc.
STOK
$26.10
-$3.94-13.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -120.80% | 1,176.88% | 60.34% | -2.86% | 2.57% |
| Total Depreciation and Amortization | -6.50% | -9.32% | -2.59% | -1.46% | -2.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.40% | -1.17% | -7.70% | -2.36% | 29.72% |
| Change in Net Operating Assets | -195.78% | 157.56% | -522.14% | -10,710.00% | 99.36% |
| Cash from Operations | -119.28% | 668.39% | -7.30% | -23.68% | 28.86% |
| Capital Expenditure | -1.32% | -261.90% | 59.22% | -123.91% | -283.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,176.05% | 1,500.93% | 102.88% | 66.11% | -982.32% |
| Cash from Investing | -1,189.18% | 1,564.47% | 102.73% | 66.01% | -983.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -59.68% | 141.90% | -93.04% | -93.24% | 6,926.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -59.68% | 141.90% | -93.04% | -93.24% | 6,926.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -218.06% | 773.36% | 49.83% | -391.78% | 215.82% |